YING Zhi-tao, HUANG Ling. The Efficacy of Polatuzumab Vedotin with Bendamustine and Rituximab （pola-BR） versus Bendamustine and Rituximab （BR） in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma[J]. Journal of Evidence-Based Medicine, 2020, 20(2): 72-75. DOI: 10.12019/j.issn.1671-5144.2020.02.002
|
Citation:
|
YING Zhi-tao, HUANG Ling. The Efficacy of Polatuzumab Vedotin with Bendamustine and Rituximab （pola-BR） versus Bendamustine and Rituximab （BR） in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma[J]. Journal of Evidence-Based Medicine, 2020, 20(2): 72-75. DOI: 10.12019/j.issn.1671-5144.2020.02.002
|
YING Zhi-tao, HUANG Ling. The Efficacy of Polatuzumab Vedotin with Bendamustine and Rituximab （pola-BR） versus Bendamustine and Rituximab （BR） in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma[J]. Journal of Evidence-Based Medicine, 2020, 20(2): 72-75. DOI: 10.12019/j.issn.1671-5144.2020.02.002
|
Citation:
|
YING Zhi-tao, HUANG Ling. The Efficacy of Polatuzumab Vedotin with Bendamustine and Rituximab （pola-BR） versus Bendamustine and Rituximab （BR） in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma[J]. Journal of Evidence-Based Medicine, 2020, 20(2): 72-75. DOI: 10.12019/j.issn.1671-5144.2020.02.002
|
DownLoad: